Final Guidance On Non-Inferiority Studies Lacks Industry-Sought Changes

One of industry's central concerns about the US FDA’s 2010 draft guidance was a "vaguely" and "subjectively" defined M2 clinical margin, but FDA did not provide a new definition in the finalized version.